nodes	percent_of_prediction	percent_of_DWPC	metapath
Mirabegron—CYP3A4—prostate cancer	0.135	1	CbGaD
Mirabegron—ORM1—Abiraterone—prostate cancer	0.0873	0.146	CbGbCtD
Mirabegron—SLCO1A2—Estrone—prostate cancer	0.0514	0.086	CbGbCtD
Mirabegron—ALB—Abiraterone—prostate cancer	0.0367	0.0614	CbGbCtD
Mirabegron—SLCO1A2—Conjugated Estrogens—prostate cancer	0.0336	0.0562	CbGbCtD
Mirabegron—SLCO1A2—Estradiol—prostate cancer	0.0295	0.0494	CbGbCtD
Mirabegron—ALB—Estrone—prostate cancer	0.0266	0.0444	CbGbCtD
Mirabegron—CYP3A4—Estradiol valerate/Dienogest—prostate cancer	0.0264	0.0442	CbGbCtD
Mirabegron—SLCO1A2—Prednisone—prostate cancer	0.0254	0.0425	CbGbCtD
Mirabegron—CYP2D6—Bicalutamide—prostate cancer	0.0218	0.0365	CbGbCtD
Mirabegron—ABCB1—Estramustine—prostate cancer	0.0216	0.0361	CbGbCtD
Mirabegron—CYP2D6—Abiraterone—prostate cancer	0.0181	0.0303	CbGbCtD
Mirabegron—ALB—Estradiol—prostate cancer	0.0153	0.0255	CbGbCtD
Mirabegron—ABCB1—Cabazitaxel—prostate cancer	0.0142	0.0238	CbGbCtD
Mirabegron—CYP3A4—Bicalutamide—prostate cancer	0.0139	0.0232	CbGbCtD
Mirabegron—ABCB1—Estrone—prostate cancer	0.0139	0.0232	CbGbCtD
Mirabegron—ALB—Prednisone—prostate cancer	0.0131	0.0219	CbGbCtD
Mirabegron—CYP3A4—Estramustine—prostate cancer	0.0129	0.0216	CbGbCtD
Mirabegron—ABCB1—Ethinyl Estradiol—prostate cancer	0.0124	0.0207	CbGbCtD
Mirabegron—CYP3A4—Abiraterone—prostate cancer	0.0115	0.0193	CbGbCtD
Mirabegron—CYP3A4—Flutamide—prostate cancer	0.0115	0.0193	CbGbCtD
Mirabegron—ABCB1—Conjugated Estrogens—prostate cancer	0.00909	0.0152	CbGbCtD
Mirabegron—CYP3A4—Cabazitaxel—prostate cancer	0.00852	0.0142	CbGbCtD
Mirabegron—CYP3A4—Estrone—prostate cancer	0.00832	0.0139	CbGbCtD
Mirabegron—ABCB1—Mitoxantrone—prostate cancer	0.00826	0.0138	CbGbCtD
Mirabegron—ABCB1—Estradiol—prostate cancer	0.00798	0.0133	CbGbCtD
Mirabegron—CYP3A4—Ethinyl Estradiol—prostate cancer	0.00742	0.0124	CbGbCtD
Mirabegron—ABCB1—Prednisone—prostate cancer	0.00686	0.0115	CbGbCtD
Mirabegron—CYP3A4—Conjugated Estrogens—prostate cancer	0.00544	0.00911	CbGbCtD
Mirabegron—ABCB1—Etoposide—prostate cancer	0.00521	0.00871	CbGbCtD
Mirabegron—CYP3A4—Mitoxantrone—prostate cancer	0.00495	0.00828	CbGbCtD
Mirabegron—CYP3A4—Estradiol—prostate cancer	0.00478	0.00799	CbGbCtD
Mirabegron—ABCB1—Docetaxel—prostate cancer	0.00477	0.00797	CbGbCtD
Mirabegron—CYP3A4—Prednisone—prostate cancer	0.00411	0.00687	CbGbCtD
Mirabegron—ABCB1—Doxorubicin—prostate cancer	0.00355	0.00594	CbGbCtD
Mirabegron—CYP2D6—Doxorubicin—prostate cancer	0.00335	0.0056	CbGbCtD
Mirabegron—CYP3A4—Etoposide—prostate cancer	0.00312	0.00522	CbGbCtD
Mirabegron—CYP3A4—Docetaxel—prostate cancer	0.00286	0.00478	CbGbCtD
Mirabegron—ADRB3—prostate gland—prostate cancer	0.00217	0.177	CbGeAlD
Mirabegron—CYP3A4—Doxorubicin—prostate cancer	0.00213	0.00356	CbGbCtD
Mirabegron—CYP3A4—urine—prostate cancer	0.00117	0.0955	CbGeAlD
Mirabegron—CYP2D6—urine—prostate cancer	0.00115	0.094	CbGeAlD
Mirabegron—ORM1—prostate gland—prostate cancer	0.00101	0.0822	CbGeAlD
Mirabegron—BCHE—prostate gland—prostate cancer	0.000625	0.0509	CbGeAlD
Mirabegron—SLCO1A2—renal system—prostate cancer	0.000606	0.0494	CbGeAlD
Mirabegron—Arbutamine—ADRB2—prostate cancer	0.000593	0.498	CrCbGaD
Mirabegron—BCHE—seminal vesicle—prostate cancer	0.000528	0.0431	CbGeAlD
Mirabegron—ORM1—bone marrow—prostate cancer	0.000519	0.0423	CbGeAlD
Mirabegron—Labetalol—ADRB2—prostate cancer	0.00042	0.354	CrCbGaD
Mirabegron—SLCO1A2—testis—prostate cancer	0.000392	0.0319	CbGeAlD
Mirabegron—ALB—testis—prostate cancer	0.000389	0.0317	CbGeAlD
Mirabegron—BCHE—bone marrow—prostate cancer	0.000322	0.0262	CbGeAlD
Mirabegron—ORM1—lymph node—prostate cancer	0.000322	0.0262	CbGeAlD
Mirabegron—ABCB1—prostate gland—prostate cancer	0.000298	0.0243	CbGeAlD
Mirabegron—CYP3A4—renal system—prostate cancer	0.000287	0.0234	CbGeAlD
Mirabegron—ALB—lymph node—prostate cancer	0.000282	0.023	CbGeAlD
Mirabegron—CYP2D6—renal system—prostate cancer	0.000282	0.023	CbGeAlD
Mirabegron—BCHE—testis—prostate cancer	0.000275	0.0224	CbGeAlD
Mirabegron—ABCB1—seminal vesicle—prostate cancer	0.000252	0.0205	CbGeAlD
Mirabegron—ABCB1—epithelium—prostate cancer	0.000219	0.0178	CbGeAlD
Mirabegron—ABCB1—renal system—prostate cancer	0.000203	0.0165	CbGeAlD
Mirabegron—BCHE—lymph node—prostate cancer	0.000199	0.0163	CbGeAlD
Mirabegron—ABCB1—urethra—prostate cancer	0.000199	0.0163	CbGeAlD
Mirabegron—CYP2D6—testis—prostate cancer	0.000182	0.0149	CbGeAlD
Mirabegron—Propafenone—CYP3A4—prostate cancer	0.000176	0.148	CrCbGaD
Mirabegron—ABCB1—bone marrow—prostate cancer	0.000153	0.0125	CbGeAlD
Mirabegron—ABCB1—testis—prostate cancer	0.000131	0.0107	CbGeAlD
Mirabegron—Tachycardia—Mitoxantrone—prostate cancer	0.000122	0.000712	CcSEcCtD
Mirabegron—Rhinitis—Docetaxel—prostate cancer	0.000122	0.000711	CcSEcCtD
Mirabegron—Asthenia—Goserelin—prostate cancer	0.000122	0.000708	CcSEcCtD
Mirabegron—Skin disorder—Mitoxantrone—prostate cancer	0.000122	0.000708	CcSEcCtD
Mirabegron—Cerebrovascular accident—Epirubicin—prostate cancer	0.000121	0.000706	CcSEcCtD
Mirabegron—Asthenia—Conjugated Estrogens—prostate cancer	0.000121	0.000701	CcSEcCtD
Mirabegron—Urinary tract disorder—Docetaxel—prostate cancer	0.00012	0.000701	CcSEcCtD
Mirabegron—Pruritus—Goserelin—prostate cancer	0.00012	0.000698	CcSEcCtD
Mirabegron—Connective tissue disorder—Docetaxel—prostate cancer	0.00012	0.000697	CcSEcCtD
Mirabegron—Urethral disorder—Docetaxel—prostate cancer	0.00012	0.000695	CcSEcCtD
Mirabegron—Pruritus—Conjugated Estrogens—prostate cancer	0.000119	0.000692	CcSEcCtD
Mirabegron—Osteoarthritis—Epirubicin—prostate cancer	0.000119	0.000692	CcSEcCtD
Mirabegron—Dyspepsia—Estradiol—prostate cancer	0.000118	0.000689	CcSEcCtD
Mirabegron—Rhinitis—Capecitabine—prostate cancer	0.000118	0.000689	CcSEcCtD
Mirabegron—Urinary tract disorder—Capecitabine—prostate cancer	0.000117	0.000678	CcSEcCtD
Mirabegron—Gastrointestinal disorder—Estradiol—prostate cancer	0.000116	0.000675	CcSEcCtD
Mirabegron—Diarrhoea—Goserelin—prostate cancer	0.000116	0.000675	CcSEcCtD
Mirabegron—Connective tissue disorder—Capecitabine—prostate cancer	0.000116	0.000675	CcSEcCtD
Mirabegron—Fatigue—Estradiol—prostate cancer	0.000116	0.000675	CcSEcCtD
Mirabegron—Urethral disorder—Capecitabine—prostate cancer	0.000116	0.000673	CcSEcCtD
Mirabegron—Erythema multiforme—Docetaxel—prostate cancer	0.000115	0.000671	CcSEcCtD
Mirabegron—Constipation—Estradiol—prostate cancer	0.000115	0.000669	CcSEcCtD
Mirabegron—Diarrhoea—Conjugated Estrogens—prostate cancer	0.000115	0.000669	CcSEcCtD
Mirabegron—Musculoskeletal discomfort—Mitoxantrone—prostate cancer	0.000114	0.000664	CcSEcCtD
Mirabegron—Purpura—Doxorubicin—prostate cancer	0.000114	0.000664	CcSEcCtD
Mirabegron—Eye disorder—Docetaxel—prostate cancer	0.000114	0.000663	CcSEcCtD
Mirabegron—Cardiac disorder—Docetaxel—prostate cancer	0.000113	0.000658	CcSEcCtD
Mirabegron—Cerebrovascular accident—Doxorubicin—prostate cancer	0.000112	0.000653	CcSEcCtD
Mirabegron—Dizziness—Goserelin—prostate cancer	0.000112	0.000653	CcSEcCtD
Mirabegron—Erythema multiforme—Capecitabine—prostate cancer	0.000112	0.000649	CcSEcCtD
Mirabegron—Dizziness—Conjugated Estrogens—prostate cancer	0.000111	0.000646	CcSEcCtD
Mirabegron—Eye disorder—Capecitabine—prostate cancer	0.00011	0.000642	CcSEcCtD
Mirabegron—Dyspepsia—Mitoxantrone—prostate cancer	0.00011	0.000642	CcSEcCtD
Mirabegron—Hypertension—Etoposide—prostate cancer	0.00011	0.000641	CcSEcCtD
Mirabegron—Osteoarthritis—Doxorubicin—prostate cancer	0.00011	0.00064	CcSEcCtD
Mirabegron—Gastrointestinal pain—Estradiol—prostate cancer	0.00011	0.00064	CcSEcCtD
Mirabegron—Cardiac disorder—Capecitabine—prostate cancer	0.00011	0.000637	CcSEcCtD
Mirabegron—Fatigue—Mitoxantrone—prostate cancer	0.000108	0.000629	CcSEcCtD
Mirabegron—Unspecified disorder of skin and subcutaneous tissue—Etoposide—prostate cancer	0.000108	0.000628	CcSEcCtD
Mirabegron—Breast disorder—Epirubicin—prostate cancer	0.000107	0.000625	CcSEcCtD
Mirabegron—Constipation—Mitoxantrone—prostate cancer	0.000107	0.000623	CcSEcCtD
Mirabegron—Aspartate aminotransferase increased—Epirubicin—prostate cancer	0.000107	0.000623	CcSEcCtD
Mirabegron—Rash—Goserelin—prostate cancer	0.000107	0.000622	CcSEcCtD
Mirabegron—Dermatitis—Goserelin—prostate cancer	0.000107	0.000622	CcSEcCtD
Mirabegron—Urticaria—Estradiol—prostate cancer	0.000107	0.000622	CcSEcCtD
Mirabegron—Abdominal pain—Estradiol—prostate cancer	0.000106	0.000619	CcSEcCtD
Mirabegron—Nasopharyngitis—Epirubicin—prostate cancer	0.000106	0.000618	CcSEcCtD
Mirabegron—Headache—Goserelin—prostate cancer	0.000106	0.000618	CcSEcCtD
Mirabegron—Rash—Conjugated Estrogens—prostate cancer	0.000106	0.000616	CcSEcCtD
Mirabegron—Dermatitis—Conjugated Estrogens—prostate cancer	0.000106	0.000616	CcSEcCtD
Mirabegron—Headache—Conjugated Estrogens—prostate cancer	0.000105	0.000612	CcSEcCtD
Mirabegron—Gastritis—Epirubicin—prostate cancer	0.000105	0.000612	CcSEcCtD
Mirabegron—Alanine aminotransferase increased—Epirubicin—prostate cancer	0.000105	0.00061	CcSEcCtD
Mirabegron—Infection—Etoposide—prostate cancer	0.000104	0.000602	CcSEcCtD
Mirabegron—Abdominal distension—Epirubicin—prostate cancer	0.000103	0.000602	CcSEcCtD
Mirabegron—Connective tissue disorder—Prednisone—prostate cancer	0.000103	0.000601	CcSEcCtD
Mirabegron—Influenza—Epirubicin—prostate cancer	0.000103	0.000598	CcSEcCtD
Mirabegron—Back pain—Docetaxel—prostate cancer	0.000103	0.000597	CcSEcCtD
Mirabegron—Gastrointestinal pain—Mitoxantrone—prostate cancer	0.000102	0.000596	CcSEcCtD
Mirabegron—Tachycardia—Etoposide—prostate cancer	0.000102	0.000592	CcSEcCtD
Mirabegron—Skin disorder—Etoposide—prostate cancer	0.000101	0.000589	CcSEcCtD
Mirabegron—Nausea—Goserelin—prostate cancer	0.000101	0.000586	CcSEcCtD
Mirabegron—Nausea—Conjugated Estrogens—prostate cancer	9.98e-05	0.000581	CcSEcCtD
Mirabegron—Urticaria—Mitoxantrone—prostate cancer	9.95e-05	0.000579	CcSEcCtD
Mirabegron—Back pain—Capecitabine—prostate cancer	9.94e-05	0.000578	CcSEcCtD
Mirabegron—Breast disorder—Doxorubicin—prostate cancer	9.94e-05	0.000578	CcSEcCtD
Mirabegron—Abdominal pain—Mitoxantrone—prostate cancer	9.91e-05	0.000576	CcSEcCtD
Mirabegron—Aspartate aminotransferase increased—Doxorubicin—prostate cancer	9.9e-05	0.000576	CcSEcCtD
Mirabegron—Nasopharyngitis—Doxorubicin—prostate cancer	9.84e-05	0.000572	CcSEcCtD
Mirabegron—Eye disorder—Prednisone—prostate cancer	9.83e-05	0.000572	CcSEcCtD
Mirabegron—Gastritis—Doxorubicin—prostate cancer	9.73e-05	0.000566	CcSEcCtD
Mirabegron—Alanine aminotransferase increased—Doxorubicin—prostate cancer	9.7e-05	0.000564	CcSEcCtD
Mirabegron—Vision blurred—Capecitabine—prostate cancer	9.68e-05	0.000563	CcSEcCtD
Mirabegron—Asthenia—Estradiol—prostate cancer	9.65e-05	0.000561	CcSEcCtD
Mirabegron—Abdominal distension—Doxorubicin—prostate cancer	9.57e-05	0.000557	CcSEcCtD
Mirabegron—Upper respiratory tract infection—Epirubicin—prostate cancer	9.55e-05	0.000556	CcSEcCtD
Mirabegron—Pruritus—Estradiol—prostate cancer	9.51e-05	0.000554	CcSEcCtD
Mirabegron—ABCB1—lymph node—prostate cancer	9.51e-05	0.00775	CbGeAlD
Mirabegron—Influenza—Doxorubicin—prostate cancer	9.51e-05	0.000553	CcSEcCtD
Mirabegron—Palpitations—Docetaxel—prostate cancer	9.38e-05	0.000546	CcSEcCtD
Mirabegron—Diarrhoea—Estradiol—prostate cancer	9.2e-05	0.000535	CcSEcCtD
Mirabegron—Hypertension—Docetaxel—prostate cancer	9.16e-05	0.000533	CcSEcCtD
Mirabegron—Infestation NOS—Epirubicin—prostate cancer	9.16e-05	0.000533	CcSEcCtD
Mirabegron—Infestation—Epirubicin—prostate cancer	9.16e-05	0.000533	CcSEcCtD
Mirabegron—Stevens-Johnson syndrome—Epirubicin—prostate cancer	9.08e-05	0.000528	CcSEcCtD
Mirabegron—Palpitations—Capecitabine—prostate cancer	9.08e-05	0.000528	CcSEcCtD
Mirabegron—Arthralgia—Docetaxel—prostate cancer	9.04e-05	0.000526	CcSEcCtD
Mirabegron—Gastrointestinal disorder—Etoposide—prostate cancer	9e-05	0.000524	CcSEcCtD
Mirabegron—Asthenia—Mitoxantrone—prostate cancer	8.99e-05	0.000523	CcSEcCtD
Mirabegron—Fatigue—Etoposide—prostate cancer	8.99e-05	0.000523	CcSEcCtD
Mirabegron—Unspecified disorder of skin and subcutaneous tissue—Docetaxel—prostate cancer	8.97e-05	0.000522	CcSEcCtD
Mirabegron—Constipation—Etoposide—prostate cancer	8.91e-05	0.000519	CcSEcCtD
Mirabegron—Urinary tract infection—Epirubicin—prostate cancer	8.9e-05	0.000518	CcSEcCtD
Mirabegron—Dizziness—Estradiol—prostate cancer	8.89e-05	0.000517	CcSEcCtD
Mirabegron—Hypertension—Capecitabine—prostate cancer	8.87e-05	0.000516	CcSEcCtD
Mirabegron—Dry mouth—Docetaxel—prostate cancer	8.84e-05	0.000514	CcSEcCtD
Mirabegron—Upper respiratory tract infection—Doxorubicin—prostate cancer	8.84e-05	0.000514	CcSEcCtD
Mirabegron—Arthralgia—Capecitabine—prostate cancer	8.75e-05	0.000509	CcSEcCtD
Mirabegron—Unspecified disorder of skin and subcutaneous tissue—Capecitabine—prostate cancer	8.69e-05	0.000505	CcSEcCtD
Mirabegron—Vision blurred—Prednisone—prostate cancer	8.63e-05	0.000502	CcSEcCtD
Mirabegron—Infection—Docetaxel—prostate cancer	8.61e-05	0.000501	CcSEcCtD
Mirabegron—Sinusitis—Epirubicin—prostate cancer	8.59e-05	0.0005	CcSEcCtD
Mirabegron—Diarrhoea—Mitoxantrone—prostate cancer	8.57e-05	0.000499	CcSEcCtD
Mirabegron—Dry mouth—Capecitabine—prostate cancer	8.56e-05	0.000498	CcSEcCtD
Mirabegron—Gastrointestinal pain—Etoposide—prostate cancer	8.52e-05	0.000496	CcSEcCtD
Mirabegron—Rash—Estradiol—prostate cancer	8.48e-05	0.000493	CcSEcCtD
Mirabegron—Infestation NOS—Doxorubicin—prostate cancer	8.48e-05	0.000493	CcSEcCtD
Mirabegron—Infestation—Doxorubicin—prostate cancer	8.48e-05	0.000493	CcSEcCtD
Mirabegron—Dermatitis—Estradiol—prostate cancer	8.47e-05	0.000493	CcSEcCtD
Mirabegron—Tachycardia—Docetaxel—prostate cancer	8.45e-05	0.000492	CcSEcCtD
Mirabegron—Headache—Estradiol—prostate cancer	8.42e-05	0.00049	CcSEcCtD
Mirabegron—Skin disorder—Docetaxel—prostate cancer	8.41e-05	0.00049	CcSEcCtD
Mirabegron—Stevens-Johnson syndrome—Doxorubicin—prostate cancer	8.4e-05	0.000489	CcSEcCtD
Mirabegron—Infection—Capecitabine—prostate cancer	8.33e-05	0.000485	CcSEcCtD
Mirabegron—Urticaria—Etoposide—prostate cancer	8.28e-05	0.000482	CcSEcCtD
Mirabegron—Rhinitis—Epirubicin—prostate cancer	8.24e-05	0.00048	CcSEcCtD
Mirabegron—Abdominal pain—Etoposide—prostate cancer	8.24e-05	0.000479	CcSEcCtD
Mirabegron—Urinary tract infection—Doxorubicin—prostate cancer	8.24e-05	0.000479	CcSEcCtD
Mirabegron—Tachycardia—Capecitabine—prostate cancer	8.19e-05	0.000476	CcSEcCtD
Mirabegron—Skin disorder—Capecitabine—prostate cancer	8.15e-05	0.000474	CcSEcCtD
Mirabegron—Urinary tract disorder—Epirubicin—prostate cancer	8.12e-05	0.000472	CcSEcCtD
Mirabegron—Connective tissue disorder—Epirubicin—prostate cancer	8.08e-05	0.00047	CcSEcCtD
Mirabegron—Urethral disorder—Epirubicin—prostate cancer	8.06e-05	0.000469	CcSEcCtD
Mirabegron—Nausea—Estradiol—prostate cancer	7.99e-05	0.000465	CcSEcCtD
Mirabegron—Sinusitis—Doxorubicin—prostate cancer	7.95e-05	0.000463	CcSEcCtD
Mirabegron—Hypertension—Prednisone—prostate cancer	7.9e-05	0.00046	CcSEcCtD
Mirabegron—Rash—Mitoxantrone—prostate cancer	7.9e-05	0.00046	CcSEcCtD
Mirabegron—Dermatitis—Mitoxantrone—prostate cancer	7.89e-05	0.000459	CcSEcCtD
Mirabegron—Musculoskeletal discomfort—Docetaxel—prostate cancer	7.89e-05	0.000459	CcSEcCtD
Mirabegron—Headache—Mitoxantrone—prostate cancer	7.85e-05	0.000457	CcSEcCtD
Mirabegron—Arthralgia—Prednisone—prostate cancer	7.79e-05	0.000453	CcSEcCtD
Mirabegron—Erythema multiforme—Epirubicin—prostate cancer	7.78e-05	0.000452	CcSEcCtD
Mirabegron—Unspecified disorder of skin and subcutaneous tissue—Prednisone—prostate cancer	7.74e-05	0.00045	CcSEcCtD
Mirabegron—Eye disorder—Epirubicin—prostate cancer	7.69e-05	0.000447	CcSEcCtD
Mirabegron—Musculoskeletal discomfort—Capecitabine—prostate cancer	7.64e-05	0.000445	CcSEcCtD
Mirabegron—Cardiac disorder—Epirubicin—prostate cancer	7.63e-05	0.000444	CcSEcCtD
Mirabegron—Rhinitis—Doxorubicin—prostate cancer	7.63e-05	0.000444	CcSEcCtD
Mirabegron—Dyspepsia—Docetaxel—prostate cancer	7.62e-05	0.000444	CcSEcCtD
Mirabegron—Urinary tract disorder—Doxorubicin—prostate cancer	7.51e-05	0.000437	CcSEcCtD
Mirabegron—Gastrointestinal disorder—Docetaxel—prostate cancer	7.48e-05	0.000435	CcSEcCtD
Mirabegron—Asthenia—Etoposide—prostate cancer	7.48e-05	0.000435	CcSEcCtD
Mirabegron—Connective tissue disorder—Doxorubicin—prostate cancer	7.48e-05	0.000435	CcSEcCtD
Mirabegron—Fatigue—Docetaxel—prostate cancer	7.47e-05	0.000434	CcSEcCtD
Mirabegron—Urethral disorder—Doxorubicin—prostate cancer	7.46e-05	0.000434	CcSEcCtD
Mirabegron—Nausea—Mitoxantrone—prostate cancer	7.44e-05	0.000433	CcSEcCtD
Mirabegron—Infection—Prednisone—prostate cancer	7.42e-05	0.000432	CcSEcCtD
Mirabegron—Constipation—Docetaxel—prostate cancer	7.41e-05	0.000431	CcSEcCtD
Mirabegron—Dyspepsia—Capecitabine—prostate cancer	7.38e-05	0.000429	CcSEcCtD
Mirabegron—Pruritus—Etoposide—prostate cancer	7.37e-05	0.000429	CcSEcCtD
Mirabegron—Tachycardia—Prednisone—prostate cancer	7.29e-05	0.000424	CcSEcCtD
Mirabegron—Skin disorder—Prednisone—prostate cancer	7.26e-05	0.000422	CcSEcCtD
Mirabegron—Gastrointestinal disorder—Capecitabine—prostate cancer	7.24e-05	0.000421	CcSEcCtD
Mirabegron—Fatigue—Capecitabine—prostate cancer	7.23e-05	0.000421	CcSEcCtD
Mirabegron—Erythema multiforme—Doxorubicin—prostate cancer	7.19e-05	0.000419	CcSEcCtD
Mirabegron—Constipation—Capecitabine—prostate cancer	7.17e-05	0.000417	CcSEcCtD
Mirabegron—Diarrhoea—Etoposide—prostate cancer	7.13e-05	0.000415	CcSEcCtD
Mirabegron—Eye disorder—Doxorubicin—prostate cancer	7.11e-05	0.000414	CcSEcCtD
Mirabegron—Gastrointestinal pain—Docetaxel—prostate cancer	7.08e-05	0.000412	CcSEcCtD
Mirabegron—Cardiac disorder—Doxorubicin—prostate cancer	7.06e-05	0.000411	CcSEcCtD
Mirabegron—Back pain—Epirubicin—prostate cancer	6.92e-05	0.000403	CcSEcCtD
Mirabegron—Dizziness—Etoposide—prostate cancer	6.89e-05	0.000401	CcSEcCtD
Mirabegron—Gastrointestinal pain—Capecitabine—prostate cancer	6.86e-05	0.000399	CcSEcCtD
Mirabegron—Abdominal pain—Docetaxel—prostate cancer	6.85e-05	0.000398	CcSEcCtD
Mirabegron—Musculoskeletal discomfort—Prednisone—prostate cancer	6.81e-05	0.000396	CcSEcCtD
Mirabegron—Vision blurred—Epirubicin—prostate cancer	6.75e-05	0.000393	CcSEcCtD
Mirabegron—Urticaria—Capecitabine—prostate cancer	6.66e-05	0.000388	CcSEcCtD
Mirabegron—Abdominal pain—Capecitabine—prostate cancer	6.63e-05	0.000386	CcSEcCtD
Mirabegron—Dyspepsia—Prednisone—prostate cancer	6.58e-05	0.000383	CcSEcCtD
Mirabegron—Rash—Etoposide—prostate cancer	6.57e-05	0.000382	CcSEcCtD
Mirabegron—Dermatitis—Etoposide—prostate cancer	6.57e-05	0.000382	CcSEcCtD
Mirabegron—Headache—Etoposide—prostate cancer	6.53e-05	0.00038	CcSEcCtD
Mirabegron—Fatigue—Prednisone—prostate cancer	6.44e-05	0.000375	CcSEcCtD
Mirabegron—Back pain—Doxorubicin—prostate cancer	6.41e-05	0.000373	CcSEcCtD
Mirabegron—Constipation—Prednisone—prostate cancer	6.39e-05	0.000372	CcSEcCtD
Mirabegron—Palpitations—Epirubicin—prostate cancer	6.33e-05	0.000368	CcSEcCtD
Mirabegron—Vision blurred—Doxorubicin—prostate cancer	6.24e-05	0.000363	CcSEcCtD
Mirabegron—Asthenia—Docetaxel—prostate cancer	6.21e-05	0.000362	CcSEcCtD
Mirabegron—Nausea—Etoposide—prostate cancer	6.19e-05	0.00036	CcSEcCtD
Mirabegron—Hypertension—Epirubicin—prostate cancer	6.18e-05	0.00036	CcSEcCtD
Mirabegron—Pruritus—Docetaxel—prostate cancer	6.13e-05	0.000357	CcSEcCtD
Mirabegron—Gastrointestinal pain—Prednisone—prostate cancer	6.11e-05	0.000355	CcSEcCtD
Mirabegron—Arthralgia—Epirubicin—prostate cancer	6.09e-05	0.000355	CcSEcCtD
Mirabegron—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—prostate cancer	6.05e-05	0.000352	CcSEcCtD
Mirabegron—Asthenia—Capecitabine—prostate cancer	6.02e-05	0.00035	CcSEcCtD
Mirabegron—Dry mouth—Epirubicin—prostate cancer	5.96e-05	0.000347	CcSEcCtD
Mirabegron—Urticaria—Prednisone—prostate cancer	5.93e-05	0.000345	CcSEcCtD
Mirabegron—Pruritus—Capecitabine—prostate cancer	5.93e-05	0.000345	CcSEcCtD
Mirabegron—Diarrhoea—Docetaxel—prostate cancer	5.93e-05	0.000345	CcSEcCtD
Mirabegron—Abdominal pain—Prednisone—prostate cancer	5.91e-05	0.000344	CcSEcCtD
Mirabegron—Palpitations—Doxorubicin—prostate cancer	5.85e-05	0.000341	CcSEcCtD
Mirabegron—Infection—Epirubicin—prostate cancer	5.8e-05	0.000338	CcSEcCtD
Mirabegron—Diarrhoea—Capecitabine—prostate cancer	5.74e-05	0.000334	CcSEcCtD
Mirabegron—Dizziness—Docetaxel—prostate cancer	5.73e-05	0.000333	CcSEcCtD
Mirabegron—Hypertension—Doxorubicin—prostate cancer	5.72e-05	0.000333	CcSEcCtD
Mirabegron—Tachycardia—Epirubicin—prostate cancer	5.7e-05	0.000332	CcSEcCtD
Mirabegron—Skin disorder—Epirubicin—prostate cancer	5.68e-05	0.00033	CcSEcCtD
Mirabegron—Arthralgia—Doxorubicin—prostate cancer	5.64e-05	0.000328	CcSEcCtD
Mirabegron—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—prostate cancer	5.6e-05	0.000326	CcSEcCtD
Mirabegron—Dizziness—Capecitabine—prostate cancer	5.55e-05	0.000323	CcSEcCtD
Mirabegron—Dry mouth—Doxorubicin—prostate cancer	5.52e-05	0.000321	CcSEcCtD
Mirabegron—Rash—Docetaxel—prostate cancer	5.46e-05	0.000318	CcSEcCtD
Mirabegron—Dermatitis—Docetaxel—prostate cancer	5.46e-05	0.000317	CcSEcCtD
Mirabegron—Headache—Docetaxel—prostate cancer	5.43e-05	0.000316	CcSEcCtD
Mirabegron—Infection—Doxorubicin—prostate cancer	5.37e-05	0.000312	CcSEcCtD
Mirabegron—Asthenia—Prednisone—prostate cancer	5.36e-05	0.000312	CcSEcCtD
Mirabegron—Musculoskeletal discomfort—Epirubicin—prostate cancer	5.32e-05	0.00031	CcSEcCtD
Mirabegron—Rash—Capecitabine—prostate cancer	5.29e-05	0.000308	CcSEcCtD
Mirabegron—Pruritus—Prednisone—prostate cancer	5.29e-05	0.000307	CcSEcCtD
Mirabegron—Dermatitis—Capecitabine—prostate cancer	5.28e-05	0.000307	CcSEcCtD
Mirabegron—Tachycardia—Doxorubicin—prostate cancer	5.28e-05	0.000307	CcSEcCtD
Mirabegron—Headache—Capecitabine—prostate cancer	5.25e-05	0.000306	CcSEcCtD
Mirabegron—Skin disorder—Doxorubicin—prostate cancer	5.25e-05	0.000305	CcSEcCtD
Mirabegron—Nausea—Docetaxel—prostate cancer	5.15e-05	0.000299	CcSEcCtD
Mirabegron—Dyspepsia—Epirubicin—prostate cancer	5.14e-05	0.000299	CcSEcCtD
Mirabegron—Diarrhoea—Prednisone—prostate cancer	5.11e-05	0.000297	CcSEcCtD
Mirabegron—Gastrointestinal disorder—Epirubicin—prostate cancer	5.04e-05	0.000293	CcSEcCtD
Mirabegron—Fatigue—Epirubicin—prostate cancer	5.04e-05	0.000293	CcSEcCtD
Mirabegron—Constipation—Epirubicin—prostate cancer	5e-05	0.000291	CcSEcCtD
Mirabegron—Nausea—Capecitabine—prostate cancer	4.98e-05	0.00029	CcSEcCtD
Mirabegron—Dizziness—Prednisone—prostate cancer	4.94e-05	0.000287	CcSEcCtD
Mirabegron—Musculoskeletal discomfort—Doxorubicin—prostate cancer	4.93e-05	0.000287	CcSEcCtD
Mirabegron—Gastrointestinal pain—Epirubicin—prostate cancer	4.78e-05	0.000278	CcSEcCtD
Mirabegron—Dyspepsia—Doxorubicin—prostate cancer	4.76e-05	0.000277	CcSEcCtD
Mirabegron—Rash—Prednisone—prostate cancer	4.71e-05	0.000274	CcSEcCtD
Mirabegron—Dermatitis—Prednisone—prostate cancer	4.71e-05	0.000274	CcSEcCtD
Mirabegron—Headache—Prednisone—prostate cancer	4.68e-05	0.000272	CcSEcCtD
Mirabegron—Gastrointestinal disorder—Doxorubicin—prostate cancer	4.67e-05	0.000272	CcSEcCtD
Mirabegron—Fatigue—Doxorubicin—prostate cancer	4.66e-05	0.000271	CcSEcCtD
Mirabegron—Urticaria—Epirubicin—prostate cancer	4.64e-05	0.00027	CcSEcCtD
Mirabegron—Constipation—Doxorubicin—prostate cancer	4.62e-05	0.000269	CcSEcCtD
Mirabegron—Abdominal pain—Epirubicin—prostate cancer	4.62e-05	0.000269	CcSEcCtD
Mirabegron—Nausea—Prednisone—prostate cancer	4.44e-05	0.000258	CcSEcCtD
Mirabegron—Gastrointestinal pain—Doxorubicin—prostate cancer	4.42e-05	0.000257	CcSEcCtD
Mirabegron—Urticaria—Doxorubicin—prostate cancer	4.29e-05	0.00025	CcSEcCtD
Mirabegron—Abdominal pain—Doxorubicin—prostate cancer	4.27e-05	0.000249	CcSEcCtD
Mirabegron—Asthenia—Epirubicin—prostate cancer	4.19e-05	0.000244	CcSEcCtD
Mirabegron—Pruritus—Epirubicin—prostate cancer	4.13e-05	0.00024	CcSEcCtD
Mirabegron—Diarrhoea—Epirubicin—prostate cancer	4e-05	0.000233	CcSEcCtD
Mirabegron—Asthenia—Doxorubicin—prostate cancer	3.88e-05	0.000226	CcSEcCtD
Mirabegron—Dizziness—Epirubicin—prostate cancer	3.86e-05	0.000225	CcSEcCtD
Mirabegron—Pruritus—Doxorubicin—prostate cancer	3.82e-05	0.000223	CcSEcCtD
Mirabegron—Diarrhoea—Doxorubicin—prostate cancer	3.7e-05	0.000215	CcSEcCtD
Mirabegron—Rash—Epirubicin—prostate cancer	3.68e-05	0.000214	CcSEcCtD
Mirabegron—Dermatitis—Epirubicin—prostate cancer	3.68e-05	0.000214	CcSEcCtD
Mirabegron—Headache—Epirubicin—prostate cancer	3.66e-05	0.000213	CcSEcCtD
Mirabegron—Dizziness—Doxorubicin—prostate cancer	3.57e-05	0.000208	CcSEcCtD
Mirabegron—Nausea—Epirubicin—prostate cancer	3.47e-05	0.000202	CcSEcCtD
Mirabegron—Rash—Doxorubicin—prostate cancer	3.41e-05	0.000198	CcSEcCtD
Mirabegron—Dermatitis—Doxorubicin—prostate cancer	3.41e-05	0.000198	CcSEcCtD
Mirabegron—Headache—Doxorubicin—prostate cancer	3.39e-05	0.000197	CcSEcCtD
Mirabegron—Nausea—Doxorubicin—prostate cancer	3.21e-05	0.000187	CcSEcCtD
Mirabegron—ABCB1—Metabolism—CYP2C19—prostate cancer	6.08e-06	7.48e-05	CbGpPWpGaD
Mirabegron—SLCO1A2—Metabolism—CREBBP—prostate cancer	6.08e-06	7.48e-05	CbGpPWpGaD
Mirabegron—ALB—Hemostasis—PIK3CB—prostate cancer	6.06e-06	7.45e-05	CbGpPWpGaD
Mirabegron—CYP2D6—Metabolism—NCOA3—prostate cancer	6.05e-06	7.43e-05	CbGpPWpGaD
Mirabegron—BCHE—Metabolism of lipids and lipoproteins—PIK3CA—prostate cancer	6.04e-06	7.42e-05	CbGpPWpGaD
Mirabegron—ADRB3—Signaling by GPCR—PIK3CA—prostate cancer	6.02e-06	7.4e-05	CbGpPWpGaD
Mirabegron—ADRB3—Signaling Pathways—MDM2—prostate cancer	5.99e-06	7.37e-05	CbGpPWpGaD
Mirabegron—CYP3A4—Metabolism—PHGDH—prostate cancer	5.97e-06	7.34e-05	CbGpPWpGaD
Mirabegron—CYP3A4—Metabolism—UMPS—prostate cancer	5.97e-06	7.34e-05	CbGpPWpGaD
Mirabegron—CYP3A4—Metabolism—ARG2—prostate cancer	5.97e-06	7.34e-05	CbGpPWpGaD
Mirabegron—ABCB1—Metabolism—GSTT1—prostate cancer	5.94e-06	7.3e-05	CbGpPWpGaD
Mirabegron—ABCB1—Metabolism—ACHE—prostate cancer	5.94e-06	7.3e-05	CbGpPWpGaD
Mirabegron—ADRB3—Signaling Pathways—ERBB2—prostate cancer	5.91e-06	7.26e-05	CbGpPWpGaD
Mirabegron—ABCB1—Metabolism—CYP2A6—prostate cancer	5.87e-06	7.21e-05	CbGpPWpGaD
Mirabegron—CYP3A4—Metabolism—LDHB—prostate cancer	5.85e-06	7.19e-05	CbGpPWpGaD
Mirabegron—ALB—Platelet activation, signaling and aggregation—AKT1—prostate cancer	5.85e-06	7.19e-05	CbGpPWpGaD
Mirabegron—ADRB3—Signaling Pathways—PIK3CB—prostate cancer	5.83e-06	7.17e-05	CbGpPWpGaD
Mirabegron—ALB—Metabolism—SLC5A5—prostate cancer	5.83e-06	7.17e-05	CbGpPWpGaD
Mirabegron—CYP2D6—Metabolism—HPGDS—prostate cancer	5.77e-06	7.09e-05	CbGpPWpGaD
Mirabegron—SLCO1A2—Metabolism—PIK3CD—prostate cancer	5.77e-06	7.09e-05	CbGpPWpGaD
Mirabegron—ABCB1—Integrated Pancreatic Cancer Pathway—AKT1—prostate cancer	5.76e-06	7.08e-05	CbGpPWpGaD
Mirabegron—BCHE—Metabolism—PIK3CG—prostate cancer	5.75e-06	7.07e-05	CbGpPWpGaD
Mirabegron—CYP3A4—Metabolism—CYP3A5—prostate cancer	5.74e-06	7.06e-05	CbGpPWpGaD
Mirabegron—CYP2D6—Metabolism—CYP2C19—prostate cancer	5.73e-06	7.05e-05	CbGpPWpGaD
Mirabegron—ABCB1—Metabolism—AKR1C3—prostate cancer	5.71e-06	7.02e-05	CbGpPWpGaD
Mirabegron—ALB—Metabolism—CYP2E1—prostate cancer	5.69e-06	7e-05	CbGpPWpGaD
Mirabegron—ABCB1—Metabolism—PRKACB—prostate cancer	5.68e-06	6.98e-05	CbGpPWpGaD
Mirabegron—ALB—Metabolism—NQO1—prostate cancer	5.63e-06	6.92e-05	CbGpPWpGaD
Mirabegron—ABCB1—Metabolism—CYP17A1—prostate cancer	5.62e-06	6.91e-05	CbGpPWpGaD
Mirabegron—ADRB3—Signaling Pathways—CXCL8—prostate cancer	5.6e-06	6.89e-05	CbGpPWpGaD
Mirabegron—CYP2D6—Metabolism—ACHE—prostate cancer	5.59e-06	6.88e-05	CbGpPWpGaD
Mirabegron—CYP2D6—Metabolism—GSTT1—prostate cancer	5.59e-06	6.88e-05	CbGpPWpGaD
Mirabegron—ALB—Hemostasis—IL2—prostate cancer	5.56e-06	6.84e-05	CbGpPWpGaD
Mirabegron—ABCB1—Transmembrane transport of small molecules—CREBBP—prostate cancer	5.56e-06	6.83e-05	CbGpPWpGaD
Mirabegron—ALB—Metabolism—TH—prostate cancer	5.55e-06	6.82e-05	CbGpPWpGaD
Mirabegron—CYP3A4—Metabolism—TCN2—prostate cancer	5.55e-06	6.82e-05	CbGpPWpGaD
Mirabegron—CYP3A4—Metabolism—PDHA1—prostate cancer	5.55e-06	6.82e-05	CbGpPWpGaD
Mirabegron—CYP3A4—Metabolism—UCP3—prostate cancer	5.55e-06	6.82e-05	CbGpPWpGaD
Mirabegron—CYP3A4—Metabolism—GSTA3—prostate cancer	5.55e-06	6.82e-05	CbGpPWpGaD
Mirabegron—CYP2D6—Metabolism—CYP2A6—prostate cancer	5.53e-06	6.8e-05	CbGpPWpGaD
Mirabegron—ALB—Metabolism of lipids and lipoproteins—PIK3CB—prostate cancer	5.51e-06	6.78e-05	CbGpPWpGaD
Mirabegron—ALB—Metabolism—CYP3A4—prostate cancer	5.49e-06	6.75e-05	CbGpPWpGaD
Mirabegron—ADRB3—Signaling Pathways—CDKN1B—prostate cancer	5.47e-06	6.73e-05	CbGpPWpGaD
Mirabegron—ALB—Metabolism of lipids and lipoproteins—PTGS2—prostate cancer	5.46e-06	6.72e-05	CbGpPWpGaD
Mirabegron—BCHE—Metabolism—INS—prostate cancer	5.45e-06	6.7e-05	CbGpPWpGaD
Mirabegron—SLCO1A2—Metabolism—NOS3—prostate cancer	5.44e-06	6.69e-05	CbGpPWpGaD
Mirabegron—ADRB3—GPCR downstream signaling—AKT1—prostate cancer	5.41e-06	6.65e-05	CbGpPWpGaD
Mirabegron—ALB—Metabolism—CYP1B1—prostate cancer	5.4e-06	6.64e-05	CbGpPWpGaD
Mirabegron—CYP2D6—Metabolism—AKR1C3—prostate cancer	5.38e-06	6.61e-05	CbGpPWpGaD
Mirabegron—ADRB3—Signaling Pathways—CASP3—prostate cancer	5.36e-06	6.59e-05	CbGpPWpGaD
Mirabegron—ABCB1—Metabolism—NCOA2—prostate cancer	5.35e-06	6.58e-05	CbGpPWpGaD
Mirabegron—ADRB3—Signaling Pathways—IL2—prostate cancer	5.35e-06	6.58e-05	CbGpPWpGaD
Mirabegron—CYP2D6—Metabolism—PRKACB—prostate cancer	5.35e-06	6.58e-05	CbGpPWpGaD
Mirabegron—BCHE—Metabolism—CREBBP—prostate cancer	5.34e-06	6.56e-05	CbGpPWpGaD
Mirabegron—ADRB3—Signaling by GPCR—IL6—prostate cancer	5.33e-06	6.55e-05	CbGpPWpGaD
Mirabegron—CYP2D6—Metabolism—CYP17A1—prostate cancer	5.3e-06	6.51e-05	CbGpPWpGaD
Mirabegron—CYP3A4—Metabolism—SLC22A3—prostate cancer	5.29e-06	6.51e-05	CbGpPWpGaD
Mirabegron—CYP3A4—Metabolism—HSD3B1—prostate cancer	5.29e-06	6.51e-05	CbGpPWpGaD
Mirabegron—ALB—Metabolism—GGT1—prostate cancer	5.23e-06	6.43e-05	CbGpPWpGaD
Mirabegron—ADRB3—Signaling Pathways—CCND1—prostate cancer	5.22e-06	6.42e-05	CbGpPWpGaD
Mirabegron—ADRB3—Signaling Pathways—CTNNB1—prostate cancer	5.17e-06	6.35e-05	CbGpPWpGaD
Mirabegron—ALB—Metabolism—NCOA1—prostate cancer	5.15e-06	6.33e-05	CbGpPWpGaD
Mirabegron—ABCB1—Metabolism—SLC5A5—prostate cancer	5.11e-06	6.28e-05	CbGpPWpGaD
Mirabegron—ALB—Metabolism—CYP19A1—prostate cancer	5.08e-06	6.24e-05	CbGpPWpGaD
Mirabegron—CYP3A4—Metabolism—GSTA4—prostate cancer	5.07e-06	6.24e-05	CbGpPWpGaD
Mirabegron—CYP3A4—Metabolism—TBXAS1—prostate cancer	5.07e-06	6.24e-05	CbGpPWpGaD
Mirabegron—ADRB3—Signaling Pathways—MMP9—prostate cancer	5.07e-06	6.23e-05	CbGpPWpGaD
Mirabegron—BCHE—Metabolism—PIK3CD—prostate cancer	5.06e-06	6.22e-05	CbGpPWpGaD
Mirabegron—ADRB3—Signaling Pathways—CDKN1A—prostate cancer	5.05e-06	6.21e-05	CbGpPWpGaD
Mirabegron—CYP2D6—Metabolism—NCOA2—prostate cancer	5.05e-06	6.2e-05	CbGpPWpGaD
Mirabegron—ADRB3—Signaling Pathways—PTEN—prostate cancer	5.04e-06	6.19e-05	CbGpPWpGaD
Mirabegron—SLCO1A2—Metabolism—PIK3CB—prostate cancer	5.03e-06	6.18e-05	CbGpPWpGaD
Mirabegron—ALB—Hemostasis—EP300—prostate cancer	4.99e-06	6.14e-05	CbGpPWpGaD
Mirabegron—ABCB1—Metabolism—CYP2E1—prostate cancer	4.99e-06	6.13e-05	CbGpPWpGaD
Mirabegron—SLCO1A2—Metabolism—PTGS2—prostate cancer	4.98e-06	6.12e-05	CbGpPWpGaD
Mirabegron—CYP3A4—Metabolism—GSTA2—prostate cancer	4.94e-06	6.08e-05	CbGpPWpGaD
Mirabegron—ABCB1—Metabolism—NQO1—prostate cancer	4.93e-06	6.07e-05	CbGpPWpGaD
Mirabegron—ADRB3—Signaling by GPCR—AKT1—prostate cancer	4.92e-06	6.04e-05	CbGpPWpGaD
Mirabegron—ALB—Metabolism—RXRA—prostate cancer	4.9e-06	6.02e-05	CbGpPWpGaD
Mirabegron—CYP3A4—Metabolism—ABCG5—prostate cancer	4.88e-06	6e-05	CbGpPWpGaD
Mirabegron—CYP3A4—Metabolism—SULT1A1—prostate cancer	4.88e-06	6e-05	CbGpPWpGaD
Mirabegron—ABCB1—Metabolism—TH—prostate cancer	4.86e-06	5.98e-05	CbGpPWpGaD
Mirabegron—ALB—Hemostasis—SRC—prostate cancer	4.85e-06	5.97e-05	CbGpPWpGaD
Mirabegron—CYP2D6—Metabolism—SLC5A5—prostate cancer	4.81e-06	5.92e-05	CbGpPWpGaD
Mirabegron—ABCB1—Metabolism—CYP3A4—prostate cancer	4.81e-06	5.91e-05	CbGpPWpGaD
Mirabegron—ADRB3—Signaling Pathways—EP300—prostate cancer	4.8e-06	5.91e-05	CbGpPWpGaD
Mirabegron—BCHE—Metabolism—NOS3—prostate cancer	4.78e-06	5.87e-05	CbGpPWpGaD
Mirabegron—CYP3A4—Metabolism—GSTA1—prostate cancer	4.77e-06	5.86e-05	CbGpPWpGaD
Mirabegron—ALB—Metabolism of lipids and lipoproteins—PTEN—prostate cancer	4.76e-06	5.86e-05	CbGpPWpGaD
Mirabegron—ABCB1—Metabolism—CYP1B1—prostate cancer	4.73e-06	5.82e-05	CbGpPWpGaD
Mirabegron—ALB—Hemostasis—VEGFA—prostate cancer	4.73e-06	5.81e-05	CbGpPWpGaD
Mirabegron—ALB—Metabolism—COMT—prostate cancer	4.72e-06	5.8e-05	CbGpPWpGaD
Mirabegron—CYP3A4—Metabolism—GSTO1—prostate cancer	4.72e-06	5.8e-05	CbGpPWpGaD
Mirabegron—CYP3A4—Metabolism—NAT2—prostate cancer	4.72e-06	5.8e-05	CbGpPWpGaD
Mirabegron—CYP3A4—Metabolism—HSD3B2—prostate cancer	4.72e-06	5.8e-05	CbGpPWpGaD
Mirabegron—CYP2D6—Metabolism—CYP2E1—prostate cancer	4.7e-06	5.78e-05	CbGpPWpGaD
Mirabegron—ALB—Metabolism—GSTP1—prostate cancer	4.7e-06	5.77e-05	CbGpPWpGaD
Mirabegron—ADRB3—Signaling Pathways—SRC—prostate cancer	4.67e-06	5.74e-05	CbGpPWpGaD
Mirabegron—CYP2D6—Metabolism—NQO1—prostate cancer	4.65e-06	5.72e-05	CbGpPWpGaD
Mirabegron—ALB—Metabolism—ITPR1—prostate cancer	4.62e-06	5.68e-05	CbGpPWpGaD
Mirabegron—CYP2D6—Metabolism—TH—prostate cancer	4.58e-06	5.63e-05	CbGpPWpGaD
Mirabegron—ABCB1—Metabolism—GGT1—prostate cancer	4.58e-06	5.63e-05	CbGpPWpGaD
Mirabegron—ADRB3—Signaling Pathways—VEGFA—prostate cancer	4.55e-06	5.59e-05	CbGpPWpGaD
Mirabegron—ALB—Metabolism of lipids and lipoproteins—EP300—prostate cancer	4.54e-06	5.59e-05	CbGpPWpGaD
Mirabegron—CYP2D6—Metabolism—CYP3A4—prostate cancer	4.53e-06	5.57e-05	CbGpPWpGaD
Mirabegron—CYP3A4—Metabolism—PLCB2—prostate cancer	4.52e-06	5.56e-05	CbGpPWpGaD
Mirabegron—CYP3A4—Metabolism—LRP2—prostate cancer	4.52e-06	5.56e-05	CbGpPWpGaD
Mirabegron—CYP3A4—Metabolism—CYP2C18—prostate cancer	4.52e-06	5.56e-05	CbGpPWpGaD
Mirabegron—ABCB1—Metabolism—NCOA1—prostate cancer	4.51e-06	5.55e-05	CbGpPWpGaD
Mirabegron—ADRB3—Signaling Pathways—STAT3—prostate cancer	4.51e-06	5.54e-05	CbGpPWpGaD
Mirabegron—CYP2D6—Metabolism—CYP1B1—prostate cancer	4.46e-06	5.48e-05	CbGpPWpGaD
Mirabegron—ABCB1—Metabolism—CYP19A1—prostate cancer	4.45e-06	5.47e-05	CbGpPWpGaD
Mirabegron—CYP3A4—Metabolism—P4HB—prostate cancer	4.43e-06	5.45e-05	CbGpPWpGaD
Mirabegron—BCHE—Metabolism—PIK3CB—prostate cancer	4.41e-06	5.42e-05	CbGpPWpGaD
Mirabegron—BCHE—Metabolism—PTGS2—prostate cancer	4.37e-06	5.37e-05	CbGpPWpGaD
Mirabegron—ALB—Metabolism—TYMS—prostate cancer	4.37e-06	5.37e-05	CbGpPWpGaD
Mirabegron—SLCO1A2—Metabolism—PTEN—prostate cancer	4.34e-06	5.34e-05	CbGpPWpGaD
Mirabegron—ALB—Hemostasis—TGFB1—prostate cancer	4.34e-06	5.33e-05	CbGpPWpGaD
Mirabegron—CYP2D6—Metabolism—GGT1—prostate cancer	4.32e-06	5.31e-05	CbGpPWpGaD
Mirabegron—ALB—Metabolism—GSTM1—prostate cancer	4.32e-06	5.31e-05	CbGpPWpGaD
Mirabegron—CYP3A4—Metabolism—SLC22A1—prostate cancer	4.31e-06	5.3e-05	CbGpPWpGaD
Mirabegron—ABCB1—Metabolism—RXRA—prostate cancer	4.29e-06	5.28e-05	CbGpPWpGaD
Mirabegron—CYP2D6—Metabolism—NCOA1—prostate cancer	4.25e-06	5.23e-05	CbGpPWpGaD
Mirabegron—ALB—Metabolism—LPL—prostate cancer	4.24e-06	5.21e-05	CbGpPWpGaD
Mirabegron—CYP3A4—Metabolism—SULT2A1—prostate cancer	4.2e-06	5.17e-05	CbGpPWpGaD
Mirabegron—CYP2D6—Metabolism—CYP19A1—prostate cancer	4.19e-06	5.15e-05	CbGpPWpGaD
Mirabegron—ADRB3—Signaling Pathways—MYC—prostate cancer	4.19e-06	5.15e-05	CbGpPWpGaD
Mirabegron—ADRB3—Signaling Pathways—TGFB1—prostate cancer	4.18e-06	5.13e-05	CbGpPWpGaD
Mirabegron—SLCO1A2—Metabolism—EP300—prostate cancer	4.14e-06	5.09e-05	CbGpPWpGaD
Mirabegron—CYP3A4—Metabolism—MED12—prostate cancer	4.14e-06	5.09e-05	CbGpPWpGaD
Mirabegron—ABCB1—Metabolism—COMT—prostate cancer	4.13e-06	5.08e-05	CbGpPWpGaD
Mirabegron—ABCB1—Metabolism—GSTP1—prostate cancer	4.11e-06	5.06e-05	CbGpPWpGaD
Mirabegron—CYP3A4—Metabolism—GNG5—prostate cancer	4.1e-06	5.04e-05	CbGpPWpGaD
Mirabegron—ADRB3—Signaling Pathways—EGFR—prostate cancer	4.1e-06	5.03e-05	CbGpPWpGaD
Mirabegron—ALB—Metabolism—CYP1A1—prostate cancer	4.09e-06	5.03e-05	CbGpPWpGaD
Mirabegron—ALB—Metabolism—ERCC2—prostate cancer	4.06e-06	4.99e-05	CbGpPWpGaD
Mirabegron—ABCB1—Metabolism—ITPR1—prostate cancer	4.05e-06	4.98e-05	CbGpPWpGaD
Mirabegron—CYP2D6—Metabolism—RXRA—prostate cancer	4.04e-06	4.97e-05	CbGpPWpGaD
Mirabegron—ALB—Hemostasis—KRAS—prostate cancer	4.02e-06	4.94e-05	CbGpPWpGaD
Mirabegron—CYP3A4—Metabolism—NCOA3—prostate cancer	3.95e-06	4.86e-05	CbGpPWpGaD
Mirabegron—CYP2D6—Metabolism—COMT—prostate cancer	3.9e-06	4.79e-05	CbGpPWpGaD
Mirabegron—CYP2D6—Metabolism—GSTP1—prostate cancer	3.88e-06	4.77e-05	CbGpPWpGaD
Mirabegron—ADRB3—Signaling Pathways—KRAS—prostate cancer	3.87e-06	4.76e-05	CbGpPWpGaD
Mirabegron—ABCB1—Metabolism—TYMS—prostate cancer	3.83e-06	4.7e-05	CbGpPWpGaD
Mirabegron—CYP2D6—Metabolism—ITPR1—prostate cancer	3.82e-06	4.69e-05	CbGpPWpGaD
Mirabegron—ALB—Metabolism—MTHFR—prostate cancer	3.81e-06	4.69e-05	CbGpPWpGaD
Mirabegron—BCHE—Metabolism—PTEN—prostate cancer	3.81e-06	4.68e-05	CbGpPWpGaD
Mirabegron—ABCB1—Metabolism—GSTM1—prostate cancer	3.78e-06	4.65e-05	CbGpPWpGaD
Mirabegron—CYP3A4—Metabolism—HPGDS—prostate cancer	3.77e-06	4.64e-05	CbGpPWpGaD
Mirabegron—CYP3A4—Metabolism—CYP2C19—prostate cancer	3.75e-06	4.61e-05	CbGpPWpGaD
Mirabegron—ALB—Metabolism—PPARA—prostate cancer	3.74e-06	4.6e-05	CbGpPWpGaD
Mirabegron—ABCB1—Metabolism—LPL—prostate cancer	3.71e-06	4.56e-05	CbGpPWpGaD
Mirabegron—ALB—Hemostasis—PIK3CA—prostate cancer	3.69e-06	4.54e-05	CbGpPWpGaD
Mirabegron—CYP3A4—Metabolism—GSTT1—prostate cancer	3.66e-06	4.5e-05	CbGpPWpGaD
Mirabegron—CYP3A4—Metabolism—ACHE—prostate cancer	3.66e-06	4.5e-05	CbGpPWpGaD
Mirabegron—BCHE—Metabolism—EP300—prostate cancer	3.63e-06	4.47e-05	CbGpPWpGaD
Mirabegron—CYP3A4—Metabolism—CYP2A6—prostate cancer	3.62e-06	4.44e-05	CbGpPWpGaD
Mirabegron—CYP2D6—Metabolism—TYMS—prostate cancer	3.6e-06	4.43e-05	CbGpPWpGaD
Mirabegron—ABCB1—Metabolism—CYP1A1—prostate cancer	3.58e-06	4.41e-05	CbGpPWpGaD
Mirabegron—ALB—Hemostasis—TP53—prostate cancer	3.57e-06	4.39e-05	CbGpPWpGaD
Mirabegron—CYP2D6—Metabolism—GSTM1—prostate cancer	3.56e-06	4.38e-05	CbGpPWpGaD
Mirabegron—ABCB1—Metabolism—ERCC2—prostate cancer	3.56e-06	4.37e-05	CbGpPWpGaD
Mirabegron—ADRB3—Signaling Pathways—PIK3CA—prostate cancer	3.55e-06	4.37e-05	CbGpPWpGaD
Mirabegron—ALB—Metabolism—CAV1—prostate cancer	3.52e-06	4.33e-05	CbGpPWpGaD
Mirabegron—CYP3A4—Metabolism—AKR1C3—prostate cancer	3.52e-06	4.32e-05	CbGpPWpGaD
Mirabegron—CYP3A4—Metabolism—PRKACB—prostate cancer	3.5e-06	4.3e-05	CbGpPWpGaD
Mirabegron—CYP2D6—Metabolism—LPL—prostate cancer	3.5e-06	4.3e-05	CbGpPWpGaD
Mirabegron—CYP3A4—Metabolism—CYP17A1—prostate cancer	3.46e-06	4.26e-05	CbGpPWpGaD
Mirabegron—ADRB3—Signaling Pathways—TP53—prostate cancer	3.44e-06	4.23e-05	CbGpPWpGaD
Mirabegron—CYP2D6—Metabolism—CYP1A1—prostate cancer	3.38e-06	4.15e-05	CbGpPWpGaD
Mirabegron—ALB—Metabolism of lipids and lipoproteins—PIK3CA—prostate cancer	3.36e-06	4.13e-05	CbGpPWpGaD
Mirabegron—CYP2D6—Metabolism—ERCC2—prostate cancer	3.35e-06	4.12e-05	CbGpPWpGaD
Mirabegron—ABCB1—Metabolism—MTHFR—prostate cancer	3.34e-06	4.11e-05	CbGpPWpGaD
Mirabegron—CYP3A4—Metabolism—NCOA2—prostate cancer	3.3e-06	4.06e-05	CbGpPWpGaD
Mirabegron—ABCB1—Metabolism—PPARA—prostate cancer	3.28e-06	4.03e-05	CbGpPWpGaD
Mirabegron—ALB—Metabolism—PIK3CG—prostate cancer	3.2e-06	3.94e-05	CbGpPWpGaD
Mirabegron—CYP2D6—Metabolism—MTHFR—prostate cancer	3.15e-06	3.87e-05	CbGpPWpGaD
Mirabegron—ADRB3—Signaling Pathways—IL6—prostate cancer	3.15e-06	3.87e-05	CbGpPWpGaD
Mirabegron—CYP3A4—Metabolism—SLC5A5—prostate cancer	3.15e-06	3.87e-05	CbGpPWpGaD
Mirabegron—CYP2D6—Metabolism—PPARA—prostate cancer	3.09e-06	3.8e-05	CbGpPWpGaD
Mirabegron—ABCB1—Metabolism—CAV1—prostate cancer	3.08e-06	3.79e-05	CbGpPWpGaD
Mirabegron—CYP3A4—Metabolism—CYP2E1—prostate cancer	3.07e-06	3.78e-05	CbGpPWpGaD
Mirabegron—SLCO1A2—Metabolism—PIK3CA—prostate cancer	3.06e-06	3.77e-05	CbGpPWpGaD
Mirabegron—CYP3A4—Metabolism—NQO1—prostate cancer	3.04e-06	3.74e-05	CbGpPWpGaD
Mirabegron—ALB—Metabolism—INS—prostate cancer	3.03e-06	3.73e-05	CbGpPWpGaD
Mirabegron—ALB—Hemostasis—AKT1—prostate cancer	3.02e-06	3.71e-05	CbGpPWpGaD
Mirabegron—CYP3A4—Metabolism—TH—prostate cancer	3e-06	3.68e-05	CbGpPWpGaD
Mirabegron—ALB—Metabolism—CREBBP—prostate cancer	2.97e-06	3.65e-05	CbGpPWpGaD
Mirabegron—CYP3A4—Metabolism—CYP1B1—prostate cancer	2.91e-06	3.58e-05	CbGpPWpGaD
Mirabegron—CYP2D6—Metabolism—CAV1—prostate cancer	2.9e-06	3.57e-05	CbGpPWpGaD
Mirabegron—ADRB3—Signaling Pathways—AKT1—prostate cancer	2.9e-06	3.57e-05	CbGpPWpGaD
Mirabegron—CYP3A4—Metabolism—GGT1—prostate cancer	2.82e-06	3.47e-05	CbGpPWpGaD
Mirabegron—ALB—Metabolism—PIK3CD—prostate cancer	2.82e-06	3.46e-05	CbGpPWpGaD
Mirabegron—ABCB1—Metabolism—PIK3CG—prostate cancer	2.81e-06	3.45e-05	CbGpPWpGaD
Mirabegron—CYP3A4—Metabolism—NCOA1—prostate cancer	2.78e-06	3.42e-05	CbGpPWpGaD
Mirabegron—CYP3A4—Metabolism—CYP19A1—prostate cancer	2.74e-06	3.37e-05	CbGpPWpGaD
Mirabegron—BCHE—Metabolism—PIK3CA—prostate cancer	2.69e-06	3.3e-05	CbGpPWpGaD
Mirabegron—ALB—Metabolism—NOS3—prostate cancer	2.66e-06	3.27e-05	CbGpPWpGaD
Mirabegron—ABCB1—Metabolism—INS—prostate cancer	2.66e-06	3.27e-05	CbGpPWpGaD
Mirabegron—CYP2D6—Metabolism—PIK3CG—prostate cancer	2.65e-06	3.25e-05	CbGpPWpGaD
Mirabegron—CYP3A4—Metabolism—RXRA—prostate cancer	2.64e-06	3.25e-05	CbGpPWpGaD
Mirabegron—ABCB1—Metabolism—CREBBP—prostate cancer	2.6e-06	3.2e-05	CbGpPWpGaD
Mirabegron—CYP3A4—Metabolism—COMT—prostate cancer	2.55e-06	3.13e-05	CbGpPWpGaD
Mirabegron—CYP3A4—Metabolism—GSTP1—prostate cancer	2.54e-06	3.12e-05	CbGpPWpGaD
Mirabegron—CYP2D6—Metabolism—INS—prostate cancer	2.5e-06	3.08e-05	CbGpPWpGaD
Mirabegron—SLCO1A2—Metabolism—AKT1—prostate cancer	2.5e-06	3.08e-05	CbGpPWpGaD
Mirabegron—CYP3A4—Metabolism—ITPR1—prostate cancer	2.49e-06	3.07e-05	CbGpPWpGaD
Mirabegron—ABCB1—Metabolism—PIK3CD—prostate cancer	2.47e-06	3.03e-05	CbGpPWpGaD
Mirabegron—ALB—Metabolism—PIK3CB—prostate cancer	2.46e-06	3.02e-05	CbGpPWpGaD
Mirabegron—CYP2D6—Metabolism—CREBBP—prostate cancer	2.45e-06	3.02e-05	CbGpPWpGaD
Mirabegron—ALB—Metabolism—PTGS2—prostate cancer	2.43e-06	2.99e-05	CbGpPWpGaD
Mirabegron—CYP3A4—Metabolism—TYMS—prostate cancer	2.36e-06	2.9e-05	CbGpPWpGaD
Mirabegron—ABCB1—Metabolism—NOS3—prostate cancer	2.33e-06	2.87e-05	CbGpPWpGaD
Mirabegron—CYP3A4—Metabolism—GSTM1—prostate cancer	2.33e-06	2.86e-05	CbGpPWpGaD
Mirabegron—CYP2D6—Metabolism—PIK3CD—prostate cancer	2.33e-06	2.86e-05	CbGpPWpGaD
Mirabegron—CYP3A4—Metabolism—LPL—prostate cancer	2.29e-06	2.81e-05	CbGpPWpGaD
Mirabegron—CYP3A4—Metabolism—CYP1A1—prostate cancer	2.21e-06	2.72e-05	CbGpPWpGaD
Mirabegron—CYP2D6—Metabolism—NOS3—prostate cancer	2.2e-06	2.7e-05	CbGpPWpGaD
Mirabegron—BCHE—Metabolism—AKT1—prostate cancer	2.2e-06	2.7e-05	CbGpPWpGaD
Mirabegron—CYP3A4—Metabolism—ERCC2—prostate cancer	2.19e-06	2.69e-05	CbGpPWpGaD
Mirabegron—ABCB1—Metabolism—PIK3CB—prostate cancer	2.15e-06	2.65e-05	CbGpPWpGaD
Mirabegron—ABCB1—Metabolism—PTGS2—prostate cancer	2.13e-06	2.62e-05	CbGpPWpGaD
Mirabegron—ALB—Metabolism—PTEN—prostate cancer	2.12e-06	2.61e-05	CbGpPWpGaD
Mirabegron—CYP3A4—Metabolism—MTHFR—prostate cancer	2.06e-06	2.53e-05	CbGpPWpGaD
Mirabegron—CYP2D6—Metabolism—PIK3CB—prostate cancer	2.03e-06	2.49e-05	CbGpPWpGaD
Mirabegron—ALB—Metabolism—EP300—prostate cancer	2.02e-06	2.49e-05	CbGpPWpGaD
Mirabegron—CYP3A4—Metabolism—PPARA—prostate cancer	2.02e-06	2.48e-05	CbGpPWpGaD
Mirabegron—CYP2D6—Metabolism—PTGS2—prostate cancer	2.01e-06	2.47e-05	CbGpPWpGaD
Mirabegron—CYP3A4—Metabolism—CAV1—prostate cancer	1.9e-06	2.33e-05	CbGpPWpGaD
Mirabegron—ABCB1—Metabolism—PTEN—prostate cancer	1.86e-06	2.29e-05	CbGpPWpGaD
Mirabegron—ABCB1—Metabolism—EP300—prostate cancer	1.77e-06	2.18e-05	CbGpPWpGaD
Mirabegron—CYP2D6—Metabolism—PTEN—prostate cancer	1.75e-06	2.15e-05	CbGpPWpGaD
Mirabegron—CYP3A4—Metabolism—PIK3CG—prostate cancer	1.73e-06	2.13e-05	CbGpPWpGaD
Mirabegron—CYP2D6—Metabolism—EP300—prostate cancer	1.67e-06	2.05e-05	CbGpPWpGaD
Mirabegron—CYP3A4—Metabolism—INS—prostate cancer	1.64e-06	2.01e-05	CbGpPWpGaD
Mirabegron—CYP3A4—Metabolism—CREBBP—prostate cancer	1.6e-06	1.97e-05	CbGpPWpGaD
Mirabegron—CYP3A4—Metabolism—PIK3CD—prostate cancer	1.52e-06	1.87e-05	CbGpPWpGaD
Mirabegron—ALB—Metabolism—PIK3CA—prostate cancer	1.5e-06	1.84e-05	CbGpPWpGaD
Mirabegron—CYP3A4—Metabolism—NOS3—prostate cancer	1.44e-06	1.77e-05	CbGpPWpGaD
Mirabegron—CYP3A4—Metabolism—PIK3CB—prostate cancer	1.33e-06	1.63e-05	CbGpPWpGaD
Mirabegron—CYP3A4—Metabolism—PTGS2—prostate cancer	1.31e-06	1.61e-05	CbGpPWpGaD
Mirabegron—ABCB1—Metabolism—PIK3CA—prostate cancer	1.31e-06	1.61e-05	CbGpPWpGaD
Mirabegron—CYP2D6—Metabolism—PIK3CA—prostate cancer	1.24e-06	1.52e-05	CbGpPWpGaD
Mirabegron—ALB—Metabolism—AKT1—prostate cancer	1.22e-06	1.5e-05	CbGpPWpGaD
Mirabegron—CYP3A4—Metabolism—PTEN—prostate cancer	1.15e-06	1.41e-05	CbGpPWpGaD
Mirabegron—CYP3A4—Metabolism—EP300—prostate cancer	1.09e-06	1.34e-05	CbGpPWpGaD
Mirabegron—ABCB1—Metabolism—AKT1—prostate cancer	1.07e-06	1.32e-05	CbGpPWpGaD
Mirabegron—CYP2D6—Metabolism—AKT1—prostate cancer	1.01e-06	1.24e-05	CbGpPWpGaD
Mirabegron—CYP3A4—Metabolism—PIK3CA—prostate cancer	8.08e-07	9.93e-06	CbGpPWpGaD
Mirabegron—CYP3A4—Metabolism—AKT1—prostate cancer	6.6e-07	8.12e-06	CbGpPWpGaD
